menu
    • menu
    [{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Idera Pharmaceuticals

    Menu

    Idera Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amster...

    Details : Tilsotolimod is an investigational, synthetic Toll-like receptor 9 agonist. Tilsotolimod (IMO-2125) has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive immune activation and may, in turn, contribute to tumor suppression ...

    Product Name : IMO-2125

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    May 17, 2022

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : AbbVie Inc

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Idera Pharmaceuticals Announces Tilsotolimod Updates

    Details : Company announced clinical updates regarding IMO-2125 (tilsotolimod), its synthetic Toll-like receptor 9 agonist has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive (T cells) immune activation.

    Product Name : IMO-2125

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    December 14, 2021

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : AbbVie Inc

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Bristol Myers Squibb

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Idera Pharmaceuticals Announces Results from Illuminate-301 Trial of Tilsotolimod + Ipilimumab in Anti-PD-1 Re...

    Details : ILLUMINATE-301 is a randomized, global, multi-center, open label Phase 3 trial comparing the efficacy of 8 mg intratumoral tilsotolimod in combination with 3 mg/kg ipilimumab versus 3 mg/kg ipilimumab alone in 481 patients with anti-PD-1 refractory advan...

    Product Name : IMO-2125

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    March 18, 2021

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Bristol Myers Squibb

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Undisclosed

    Deal Size : $20.7 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million

    Details : The Company plans to use the $10.0 million in cash proceeds to fund the completion of the ongoing ILLUMINATE-301 clinical trial and potential NDA filing of its lead product, tilsotolimod, for the treatment of anti-PD-1 refractory metastatic melanoma.

    Product Name : IMO-2125

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    December 15, 2020

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Undisclosed

    Deal Size : $20.7 million

    Deal Type : Private Placement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037

    Details : This new coverage expands protection of the first tilsotolimod method-of-use patent, which was directed to methods of treating metastatic melanoma and was issued in November 2019.

    Product Name : IMO-2125

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    September 28, 2020

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020

    Details : ILLUMINATE-204 is a multi-center, two-arm phase 1/2 trial in patients with anti-PD-1 refractory advanced melanoma. The phase 1 portion of the trial tested the safety and efficacy of increasing doses of tilsotolimod in combination with either Yervoy®* or...

    Product Name : IMO-2125

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    September 15, 2020

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Undisclosed

    Deal Size : $20.0 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million

    Details : The Company plans to use the initial proceeds and, if exercised, subsequent proceeds from the financing for the ongoing clinical development of tilsotolimod, its potential NDA filing and commercial launch, and for general corporate purposes.

    Product Name : IMO-2125

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    July 15, 2020

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Undisclosed

    Deal Size : $20.0 million

    Deal Type : Private Placement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Undisclosed

    Deal Size : $20.7 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million

    Details : The Company plans to use the proceeds to fund the completion, of the ongoing ILLUMINATE-301 clinical trial of its lead product, tilsotolimod, for anti-PD-1 refractory metastatic melanoma.

    Product Name : IMO-2125

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    July 04, 2020

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Undisclosed

    Deal Size : $20.7 million

    Deal Type : Private Placement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Idera Pharmaceuticals completes enrollment in registrational trial

    Details : ILLUMINATE-301 is comparing the effectiveness of intratumoral tilsotolimod in combination with ipilimumab with ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma.

    Product Name : IMO-2125

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    May 03, 2020

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed

    Idera Pharmaceuticals

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Idera Pharmaceuticals Announces Final Clinical Safety And Efficacy Data From Illuminate-204 Trial In Advanced ...

    Details : The combination regimen was generally well tolerated among the 62 patients receiving tilsotolimod at any dose in combination with Yervoy® in the ILLUMINATE-204 clinical trial.

    Product Name : IMO-2125

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    April 21, 2020

    Lead Product(s) : Tilsotolimod,Ipilimumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth